

Safety Assessment on Cannabidiol (CBD) Used as a Novel Food for Use in Food Supplements (RP354)

Food Standards Agency¹, Food Standards Scotland²

¹ Regulated Products Risk Assessment, Food Standards Agency, UK, ² Risk Assessment, Food Standards Scotland, UK

Keywords: Regulated Products, CBD, Novel foods, Safety assessment

<https://doi.org/10.46756/001c.129890>

FSA Research and Evidence

An application was submitted to the Food Standards Agency (FSA) and Food Standards Scotland (FSS) in February 2021 from Bridge Farm Group (“the applicant”) for the authorisation of cannabidiol (CBD) isolate as a novel food.

The novel food is a ≥98% pure form CBD isolate which is intended to be used as a food ingredient in food supplements for adults (excluding pregnant and lactating women, and other specifically identified vulnerable groups, including those taking medication and the immunosuppressed).

The novel food was assessed based on the data provided. This review indicated it was appropriate for the provisional acceptable daily intake ADI for 98% or greater CBD to form part of the evidence for this assessment. For CBD a provisional ADI of 10 mg/day for a healthy 70 kg adult has been published by the FSA and was considered in assessing this novel food.

The Advisory Committee on Novel Foods and Processes (ACNFP) reviewed the dossier and supplementary information provided by the applicant. The Committee did not consider any potential health benefits or claims arising from consuming the food, as the focus of the novel food assessment is to ensure the food is safe and not putting consumers at a nutritional disadvantage.

The FSA and FSS concluded, based on the advice of the ACNFP, that the applicant had provided sufficient information to assure the novel food, CBD isolate, was safe under the proposed conditions of use. The anticipated intake levels and the proposed use in food supplements was not considered to be nutritionally disadvantageous.

This safety assessment represents the opinions of the FSA and FSS.

This is a joint FSA and FSS publication.



1. Introduction

FSA and FSS have undertaken safety assessments for CBD isolate under the novel foods legislation, assimilated Regulation (EU) 2015/2283. To support the safety assessment, the ACNFP provided the advice outlined in this opinion to the FSA and FSS.

The evaluation by the ACNFP assessed the food safety risks of the novel food and its production, in line with Article 7 of assimilated Commission Implementing Regulation (EU) 2017/2469. The regulatory framework and the technical guidance put in place by the European Food Safety Agency (EFSA) for full novel food applications is used as the basis and structure for the assessment (EFSA NDA Panel, 2016).

An application was submitted to the Food Standards Agency (FSA) and Food Standards Scotland (FSS) in February 2021 from Bridge Farm Group ("the applicant") for the authorisation of cannabidiol (CBD) isolate as a novel food. The novel food is a $\geq 98\%$ pure form CBD isolate which is intended to be used as a food ingredient in food supplements for adult (excluding pregnant and lactating women, and other specifically identified vulnerable groups including those taking medication and the immunosuppressed).

The final advice from the ACNFP was agreed at the 169th meeting, allowing the FSA and FSS to complete the risk assessment.

This document outlines the conclusions of the FSA and FSS on the safety of a $\geq 98\%$ pure form CBD isolate (as detailed in application RP354) as a novel food.

2. Assessment

2.1. Identity of the Novel Food

The novel food is a cannabidiol (CBD) isolate in the form of a white to off-white crystalline powder of purity equal to or greater than 98.0%. Information to support this characterisation was provided for five batches of the novel food.

CBD is characterised by the chemical formula: $C_{21}H_{30}O_2$; molecular mass: 314.46 g/mol; CAS number: 13956-29-1; IUPAC name: 2-[(1R,6R)-6-Isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol




Diagram 1. The molecular structure of CBD

Confirmation of its identity and purity was provided by quantitative nuclear magnetic resonance spectroscopy (q-NMR) and liquid chromatography-tandem mass spectrometry (LC-MS/MS).

2.2. Production Process

The CBD isolate is manufactured using a multi-step process under controlled conditions.

Certificates of analysis for raw starting materials used in the extraction process were provided to demonstrate the effectiveness of the controls at this point in the process. The details of the commercially sensitive extraction process were shared and reviewed by the ACNFP.

Plants are grown under conditions of good horticultural practice until the flowers have matured. Biomass is harvested, dried and treated to convert cannabidiolic acid (CBDA) to cannabidiol (CBD). CBD is extracted from the treated biomass using subcritical liquid carbon dioxide as the solvent. The CBD is further purified by absorbing it onto an appropriate matrix and preferentially eluting it using subcritical liquid carbon dioxide. The purified CBD is recovered by allowing the carbon dioxide to evaporate.

The FSA and FSS considered whether the use of solvents as processing aids resulted in residues that require highlighting to risk managers. To assess the safety of the solvent residues that remain in the novel food, comparison was made to residue limits for other consumed products as detailed in [Table 1](#).

Table 1. Comparison of information on permitted residue levels for solvents used in the novel foods production compared to the proposed specification.

Solvent used	Available data on safe maximum level of consumption	Level in specification for the novel food
Subcritical liquid carbon dioxide	Commission Regulation (EU) No 231/2012. Content not less than 99 % v/v on the gaseous basis*	NA

* = [Regulation - 231/2012 - EN - EUR-Lex \(europa.eu\)](https://eur-lex.europa.eu/eli/reg/2012/231/oj)

The evidence presented (see [Table 2](#) below) on composition indicates compliance with the specification for residues of solvents. When considered at the level of consumption the evidence suggests the levels of solvent residues in the novel food are below those which would represent a safety concern.

A HACCP statement was provided along with further details of the process and how it operates. Further information on how the production process is effectively managed was requested; the applicant provided reassurance on this by evidencing the control procedures in place. The FSA and FSS concluded the production process has characterised the potential hazards and detailed the corresponding control measures sufficiently.

2.3. Compositional Information

Results from five independent batches of the novel food demonstrated that the CBD content is produced consistently. The data is presented in [Tables 2 to 6](#) below.

The data presented in [Table 2](#) indicates CBD content is consistently above 98% purity with negligible amounts of starting materials detected across the five representative batches.

It is recognised that the detection and characterisation of cannabinoids in a range of food matrices is an evolving area and there are yet to be internationally recognised methods. The limitations of available analytical methodology have been subject to discussion in the Joint ACNFP and COT CBD Subgroup and remain a source of uncertainty in this assessment.

Table 2. Compositional analysis of representative batches of cannabidiol (CBD) isolate

Parameter	Method of Analysis	Specification/ RL	Batch 1	Batch 2	Batch 3	Batch 4	Batch 5
CBD Purity (%)	qNMR	Corresponds to reference	100.1	98.8	99.1	98.5	98.9
CBC (mg/kg)	LC-MS/MS	2.5	< 2.5	< 2.5	< 2.5	< 2.5	< 2.5
CBC-A (mg/kg)	LC-MS/MS	2.5	< 2.5	< 2.5	< 2.5	< 2.5	< 2.5

Parameter	Method of Analysis	Specification/ RL	Batch 1	Batch 2	Batch 3	Batch 4	Batch 5
CBD-A (mg/kg)	LC-MS/MS	2.5	< 15	< 15	< 15	< 15	< 15
CBD-V (mg/kg)	LC-MS/MS	2.5	> 500	> 500	> 500	> 500	> 500
CBDV-A (mg/kg)	LC-MS/MS	2.5	< 1	< 1	< 1	< 1	< 1
CBG (mg/kg)	LC-MS/MS	20	< 20	< 20	< 20	< 20	< 20
CBG-A (mg/kg)	LC-MS/MS	2.5	< 1.75	< 1.75	< 1.75	< 1.75	< 1.75
CBN (mg/kg)	LC-MS/MS	2.5	< 2.5	< 1.75	< 1.75	< 2.5	< 1.75
Delta-8-THC (mg/kg)	LC-MS/MS	2.5	< 15	16.8	10.7	< 15	< 2.5
Delta-9-THC (mg/kg)	LC-MS/MS	2.5	185	137	129	86	42
THC-A (mg/kg)	LC-MS/MS	5	< 5	< 5	< 5	< 5	< 5
THC-V (mg/kg)	LC-MS/MS	2.5	< 1.75	< 1.75	< 1.75	< 1.75	< 1.75
THCV-A (mg/kg)	LC-MS/MS	2.5	< 1	< 1	< 1	< 1	< 1

qNMR = Quantitative nuclear magnetic resonance spectroscopy; RL = Reporting limit; MS/MS = Tandem mass spectrometry; LC-MS = Liquid chromatography-mass spectrometry

Analytical data concerning the microbiological content from five independent batches of the novel food were reported (Table 3). The process in manufacturing this novel food uses subcritical liquid carbon dioxide as an extraction solvent, high temperature steps, and drying, which may mitigate the proliferation of microbes within the final product. The microbiological data presented confirm that the novel food does not raise a safety concern and consistently meets the proposed microbial specification levels.

Table 3. The microbiological analysis of the novel food

Parameter*	Batch 1	Batch 2	Batch 3	Batch 4	Batch 5
Total viable cell count (CFU/g)	< 10	< 10	< 10	< 10	< 10
Total coliforms (CFU/g)	< 10	< 10	< 10	< 10	< 10
<i>Escherichia coli</i> (<i>E. coli</i>) (CFU/g)	< 10	< 10	< 10	< 10	< 10
Yeasts/ Moulds (CFU/g)	< 100	< 100	< 100	< 100	< 100
<i>Salmonella</i> spp. (/25 g)	Absent	Absent	Absent	Absent	Absent

* = Internally developed and validated methods used for analyses
CFU = Colony forming units

Results from the mycotoxin analysis for five independent representative batches of isolated CBD are presented in [Table 4](#). The data show that the isolated CBD consistently complies with the specifications set for mycotoxins within the final product.

Table 4. The mycotoxin analysis of the novel food

Parameter	Method of Analysis	Specification/ RL	Batch 1	Batch 2	Batch 3	Batch 4	Batch 5
Aflatoxin B ₁ (µg/kg)	HPLC-FD	0.02	< 0.02	< 0.02	< 0.02	< 0.02	< 0.02
Aflatoxin B ₂ (µg/kg)	HPLC-FD	0.02	< 0.02	< 0.02	< 0.02	< 0.02	< 0.02
Aflatoxin G ₁ (µg/kg)	HPLC-FD	0.02	< 0.02	< 0.02	< 0.02	< 0.02	< 0.02
Aflatoxin G ₂ (µg/kg)	HPLC-FD	0.02	< 0.02	< 0.02	< 0.02	< 0.02	< 0.02
Ochratoxin A (µg/kg)	HPLC-FD	0.02	< 0.02	< 0.02	< 0.02	< 0.02	< 0.02
Total aflatoxins (µg/kg)	HPLC-FD	0.08	< 0.08	< 0.08	< 0.08	< 0.08	< 0.08

HPLC-FD = High performance liquid chromatography-fluorescence detection

Novel food products must comply with the legal requirements for heavy metal contaminants in food. Analytical data, presented for five independent batches of the novel food, demonstrated that heavy metals were present in low quantities and below established EU limits where applicable (applicable for arsenic, cadmium, mercury and lead) ([Table 5](#)).

Table 5. Elemental Impurities in the novel food

Parameter	Method of Analysis	Specification/ RL	Batch 1	Batch 2	Batch 3	Batch 4	Batch 5
Elemental Impurities (Arsenic, mg/kg)	ICP-MS	0.02	< 0.02	< 0.02	< 0.02	< 0.02	< 0.02
Elemental Impurities (Cadmium, mg/kg)	ICP-MS	0.005	< 0.005	< 0.005	< 0.005	< 0.005	< 0.005
Elemental Impurities (Chromium, mg/kg)	ICP-MS	0.05	0.73	3.09	1.14	1.47	1.67
Elemental Impurities (Copper, mg/kg)	ICP-MS	0.05	0.13	0.42	0.11	0.18	0.11
Elemental Impurities	ICP-MS	0.005	< 0.005	< 0.005	< 0.005	< 0.005	< 0.005

Parameter	Method of Analysis	Specification/ RL	Batch 1	Batch 2	Batch 3	Batch 4	Batch 5
(Lead, mg/kg)							
Elemental Impurities (Mercury, mg/kg)	ICP-MS	0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01
Elemental Impurities (Nickel, mg/kg)	ICP-MS	0.02	< 0.02	0.6	< 0.02	0.2	0.2
Elemental Impurities (Zinc, mg/kg)	ICP-MS	0.2	< 0.2	< 0.2	< 0.2	< 0.2	< 0.2

ICP-MS = Inductively coupled plasma mass spectrometry

Results from the residual solvent analysis and pesticide analysis for five independent representative batches of isolated CBD are presented in [Table 6](#). The data show that the isolated CBD is able to consistently comply with the specifications set for residual solvents and pesticides within the final product.

Table 6. Residual solvents and pesticides analysis in novel food

Parameter	Method of Analysis	Specification/ RL	Batch 1	Batch 2	Batch 3	Batch 4	Batch 5
Residual Solvent (Methanol, mg/kg)	GC-MS	6	< 6	< 6	< 6	< 6	< 6
Residual Solvent (Ethanol, mg kg)	GC-MS	6	< 6	< 6	< 6	< 6	< 6
Residual Solvent (Isopropyl alcohol, mg/kg)	GC-MS	6	< 6	< 6	< 6	< 6	< 6
Residual Solvent (Acetone, mg/kg)	GC-MS	6	< 6	< 6	< 6	< 6	< 6
Pesticide Screen	GC-MS; LC-MS	0.01	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01

GC-MS = Gas chromatography-mass spectrometry; LC-MS = liquid chromatography-mass spectrometry

THC as a Potential Contaminant in the Novel Food

The extraction process may result in other cannabinoids remaining as contaminants. In particular, delta-9-tetrahydrocannabinol (Δ 9-THC) and its precursor acid delta-9-tetrahydrocannabinolic acid (Δ 9-THCA) were analysed due to the potential for toxic effects resulting from their consumption and the status of Δ 9-THC as a controlled drug within the UK ([Table 2](#)). Along with Δ 9-THC, other minor cannabinoids which occur at contaminant levels have the potential to play a role in the toxicity of CBD novel food products; as such, they require due consideration and monitoring to ensure the novel foods remain safe. As a result, the robustness, accuracy, and precision of the methods have been considered in interpreting the data on Δ 9-THC and were considered appropriate in this case.

A literature review was undertaken as part of the assessment of CBD as a novel food, to understand the impact on the safety of foods with trace levels of contamination with Δ 9-THC. The Joint ACNFP and COT Subgroup reviewed the information from literature and identified a point of departure from the European Food Safety Authority (EFSA) opinion on Δ 9-THC as a contaminant in milk and meat (EFSA, 2015).

Evidence from an EFSA review by the CONTAM panel suggested a point of departure from a LOAEL (lowest observed adverse effect level) of 0.036 mg/kg/bw/day, which is drawn from the most sensitive individuals and at the lowest dose tested in the clinical studies that were reviewed (EFSA, 2015). Uncertainty factors were then applied to identify a safe upper intake level. These included a factor of 3 to extrapolate from a LOAEL to a NOAEL (no observed adverse effect level), which was considered appropriate as the effects are mild to moderate in severity. A further factor of 10 was applied for person-to-person variation, resulting in total of an applied uncertainty factor of 30. This resulted in a safe upper intake level of 1 μ g/kg bw/day for Δ 9-THC consumed as a contaminant in food. This was identified an acute reference dose (ARfD) (EFSA, 2015).

The Subgroup agreed the acute reference dose (ARfD) to be sufficiently protective to apply to the UK population. It was noted that in applying the acute reference dose, EFSA has assumed that the effects seen would be the same if humans were exposed to multiple doses of THC at very low levels (EFSA, 2015). The Subgroup commented that there were no data to verify this assumption, but if setting limits the dataset is the best available.

The analysis for delta-9-tetrahydrocannabidiol as a potential contaminant in the novel food was declared as 42 – 185 mg/kg in the five batches tested, ([Table 2](#)), with a reporting limit of 2.5 mg/kg.

The levels of Δ 9-THC, where detected in the novel food, once adjusted to reflect the proposed use of 10 mg of CBD being consumed a day, were below the ARfD identified by EFSA of 1 μ g/kg bw/day or 70 μ g/day for a healthy adult. This level does not present a concern in terms of consumer safety for the novel food under the proposed conditions of use.

To ensure Δ 9-THC levels remain consistently low in the production of CBD, THC and its precursor acid combined should be a standard substance included in the specification as relevant to all batches produced.

The data presented did not indicate any additional hazards for inclusion in the specification.

2.4. Stability

The stability of the novel food was assessed in real-time under the recommended storage conditions (4°C) in five batches for 6 months. Results showed that the novel food meets the specification criteria for CBD and other cannabinoid content over this time period.

Stability results for the CBD isolate preparation using a model system based on a 1% solution of CBD in different vegetable oils was reviewed. The accelerated shelf-life study was performed at 60°C for 24 days in clear glass packaging in full light conditions. The results of this study were interpreted and demonstrated the CBD isolate is stable for 12 months in hemp oil.

The data provided supports the stability of CBD isolate for a period of at least 12 months.

2.5. Specification

The applicant's specification parameters reported in [Table 7](#) were assessed using internationally recognised methods or determined using internally developed and validated methods. The results of the analysis are detailed in [Table 2 to 6](#) and indicate the novel food can be produced consistently to the specification.

Table 7. Specification of the novel food

Description		
Cannabidiol is an amorphous powder produced by a multistep extraction process		
Parameter	Specification	Method
CBD (%)	>98.5	HPLC
CBDV (%)	< 1.0	HPLC
Delta-9-THC (%)	< 0.05	GC-MS
Terpenes (%)	< 2	-----
Sesquiterpenes (predominately humulene, caryophyllene and alpha bisabolol) (%)	< 2	GC-FID

Description		
Monoterpenes (predominantly myrcene, alpha pinene and beta pinene) (%)	< 1	GC-FID
Other (%)	< 1	-----
Plant cuticle waxes (predominantly long chain alkanes C ₂₇ -C ₃₃) (%)	< 1	GC-FID
Metals	-----	-----
Arsenic (mg/kg)	< 0.02	ICPMS
Cadmium (mg/kg)	< 0.005	ICPMS
Chromium (mg/kg)	< 4.00	ICPMS
Copper (mg/kg)	< 1.00	ICPMS
Lead (mg/kg)	< 0.01	ICPMS
Mercury (mg/kg)	< 0.01	ICPMS
Nickel (mg/kg)	< 1.00	ICPMS
Zinc (mg/kg)	< 0.2	ICPMS
Pesticides	Compliance with national limits	GCMS-MRM / LCMS-MRM

CBD = Cannabidiol; HPLC = High-performance liquid chromatography; THC = Tetrahydrocannabinol; GC-MS = Gas chromatography-mass spectrometry; GC-FID = Gas chromatography-flame ionization detection; ICPMS = Inductively coupled plasma mass spectrometry; MRM = Multiple reaction monitoring.

The information provided is sufficient for the specification of CBD and appropriately characterises the novel food seeking authorisation.

2.6. History of Use

Hemp has been widely consumed in the UK and EU as a seed oil, in tea and as an alternative to hops in beer. Extracts of hemp including CBD and synthetic CBD have not been widely consumed and are considered novel foods. While CBD products are widely available on the UK high street, indicating some consumption of CBD as a food, at the time of publication, no previous applications for CBD have yet received authorisation as a novel food.

As detailed in the COT review of the literature there has been use of both hemp-derived and synthetic forms of CBD for medicinal purposes. These provide an indication of the toxicological effects that should be explored in the testing regime – primarily effects on liver and thyroid, and potential impacts on reproductive organs. Also reported are behavioural effects such as somnolence (sleepiness) (COT, 2020).

As reported in the COT review of the publicly available data on CBD and summary data on a medicinal product, signs of adverse effects on the liver were observed at doses of CBD as low as 5 mg/kg bw/day in patients and healthy human volunteers; this dose is equivalent to 350 mg in a 70 kg adult. The data in the literature also suggested that humans might be more sensitive to the adverse effects of CBD in the liver than laboratory animals.

Somnolence effects were noted at doses ≤ 10 mg/kg bw/day in human studies. Inhibitory drug-drug interactions have also been observed with some medications when CBD is co-administered at doses of 1 mg/kg bw/day (equivalent to 70 mg in a 70 kg adult); the likelihood of effects at lower doses has not been determined (COT, 2020). Based on the COT assessment, therefore, the FSA concluded in February 2020 that 1 mg/kg bw/day, or 70 mg in a 70 kg adult, of CBD represented a pragmatic upper level of intake above which there would be clear concerns about safety, until further data are available.

It is noted that the doses used for medicinal purposes are higher than those proposed for food use. The purpose of an assessment for medicines authorisation is different to that for food and this is reflected in the data requirements. Unlike medicines, there is no risk-benefit context in foods with the requirement instead being that the products are safe. This means that outcomes that are considered an adverse event for food might not be considered as such in a medicinal study.

Within the literature, further human studies utilising chemically derived CBD provides further evidence of a history of synthetic CBD use (Izegelov et al., 2020; Klotz et al., 2019; Stero Biotech Ltd., 2020; Wheless et al., 2019). A review by Huestis et al., 2019 of Cannabidiol Adverse effects and Toxicity notes that, while CBD is not risk-free, severe adverse events occur at doses higher than those recommended for human pharmacotherapies which are prescribed to treat forms of epilepsy.

The data on previous consumption of CBD suggest areas for careful consideration in the toxicological review to understand potential effects at the lower doses used in foods.

2.7. Proposed Use and Anticipated Intake

The proposed use for the novel food is food supplements as defined by The Food Supplements (England, Scotland and Wales) Regulations 2003 as capsules, liquid or drops in dose form.

The applicant initially proposed a use level of 40 mg/day CBD for the novel food in adults (excluding pregnant and lactating women, and other specifically identified vulnerable groups including those taking medication and the immunosuppressed). As a result of consultation with the applicant the proposed uses have been updated to reflect the provisional acceptable daily intake (ADI) for the use of $\geq 98\%$ pure form CBD established at 10 mg per day (ACNFP and COT, 2023). The proposed maximum use levels for the novel food are outlined in [Table 8](#).

Table 8. Amended proposed uses and maximum use levels for the novel food

Food Category	Maximum intake level from product use
Food Supplements (for adults) as defined in the Food Supplements (England) Regulations 2003 and other equivalent legislation in the other nations of the UK as capsules, liquid or drops in dose form intended for those 18 years of age or over, excluding pregnant and lactating women and other specifically identified vulnerable groups.	10 mg per day

It is noted that consumers may be exposed to CBD from a range of food categories. The standard methodology for calculating exposure for a novel food would explore intake from a range of sources and ensure that exposure via the proposed uses would not exceed any safety level identified when consumption of the food category was analysed. It is noted that for CBD that there are already many products available. As such, the assessment has been made on the basis of identification of a maximum level of CBD that can be consumed per day. As such proposed uses will only be considered safe within the assessment when at a maximum consumption of 10 mg of CBD per day from all sources (as concluded in section 2.10 of this assessment).

Concerns were raised by the Committee regarding the potential for foreseeable misuse of CBD if consumed in multiple formats on a single day. This is because of the increased risk of consuming CBD above the provisional acceptable daily intake (ADI). The scope of the assessment is restricted to the uses proposed and any further uses or additional food categories would be subject to the change in conditions of use process. Risk managers must consider whether consumers would benefit from information on the CBD content of foods in order to ensure their consumption does not exceed the maximum intake of 10 mg per day for a healthy adult.

As recommended in the ACNFP and COT statement on CBD of 98% purity, "The provisional ADI is recommended, subject to the existing advice to consumers that pregnant and breastfeeding women and people taking any prescription medication should avoid the consumption of CBD if possible. Consumers on regular medications should seek advice from a medical professional before using any type of CBD food product. In addition, children and prospective parents trying for a baby are advised against consumption of CBD, as are those who are immunosuppressed, due to remaining data gaps and residual uncertainties concerning the safety of CBD for these groups of consumers" (ACNFP and COT, 2023).

The ACNFP explored the potential for foreseeable misuse of the novel food. They advised that the availability of multiple formats of the novel food could create conditions where exposure estimates are exceeded. It is

highlighted to risk managers that they may wish to consider whether risk management measures are needed beyond those in the food supplements regulation to ensure consumers are aware of the provisional ADI of 10 mg CBD/day for the product, a dose at which it is considered that no adverse effects would be expected.

It is also strongly recommended that risk managers consider how consumers can be supported to manage their intake appropriately within the safe limits identified and appreciate the nature of the potential risks at higher doses, for uses that are not in dosed forms.

The food supplement products are to be labelled in accordance with the labelling requirements of Food Supplements (England) Regulations 2003 and the equivalent legislation in the nations of GB. The ACNFP recommended that the applicant's proposed warning labelling be updated to include information on not exceeding the safe limit of 10 mg/day for a 70 kg healthy adult, that the product is not suitable for use under the age of 18 or for use during pregnancy or breastfeeding. As well as information on its suitability if consumers are taking medication or have existing health conditions.

2.8. Absorption, Distribution, Metabolism and Excretion (ADME)

The Absorption, Distribution, Metabolism and Excretion (ADME) of CBD are known to be complicated by the food matrix in which the CBD is delivered and are currently still being defined by professional bodies.

The oral bioavailability of CBD is low, indicating that it is not absorbed to any notable extent following ingestion (Mechoulam et al., 2002). Published works report the bioavailability of CBD to be between 13 and 19% (Grotenhermen, 2003) or 6% (Hawksworth & McArdle, 2004). The low systemic availability was demonstrated by Martin-Santos et al., 2012 and further supported by a literature search which identified the pharmacokinetics of CBD in humans (Millar et al., 2018). The COT statement on CBD of 2020 noted that although CBD has low fasting bioavailability (<10%), consumption with food could increase CBD uptake, by for example, 5-fold if eaten with a high fat meal. As such the potential for matrix effects that impact bioavailability cannot be ruled out. The applicant has submitted additional information in the form of a pharmacokinetic study, which was reviewed by the ACNFP (Johnson et al., 2022).

Following oral consumption, CBD is extensively metabolised in the liver. This rapid first pass metabolism contributes to the low oral bioavailability reported in the literature (Taylor et al., 2018; WHO, 2018). *In vitro* studies indicate that CYP3A4 and CYP2C19 are the primary hepatic enzymes responsible for first-pass metabolism of CBD; however, several other

hepatic cytochrome P450 isoforms (CYP1A1, CYP1A2, CYP2C9, CYP2D6, and CYP3A5) have also demonstrated a capability of metabolising CBD (Jiang et al., 2011; Zendulka et al., 2016).

The metabolism of CBD is thought to follow two separate pathways. One is P450-mediated, in which CBD is metabolised into its major metabolite 7-COOH-CBD. This is followed by further metabolic reactions which yield the minor metabolites of CBD, including 6-OH-CBD (Devinsky et al., 2018; Taylor et al., 2018). The other involves decarboxylation (Kraemer et al., 2019). The resultant metabolites are predominantly excreted in faeces and urine (Hawksworth & McArdle, 2004; WHO, 2018).

Multiple dosing with CBD is associated with a steady state concentration up to 2-fold accumulation of CBD in plasma when compared with a single dose (Taylor et al., 2018). Minimal evidence of plasma accumulation has also been reported in dosing studies over 5–9 days (Millar et al., 2018; Sellers et al., 2013; Stott et al., 2013).

The pharmacokinetics of CBD have been systematically reviewed by Millar *et al.* (2018) in 24 studies, most of which assessed the administration of CBD at doses of 5–20 mg/day. This correlates to a low dose application similar to this CBD novel food application. Following oral administration, single doses of 5.4 and 10 mg CBD achieved peak serum concentrations (C_{max}) of 0.9 and 2.5 ng/mL. The time to maximum concentration (T_{max}) was approximately 1 hour, with a half-life between 1 and 3 hours. Given the intended use of this CBD as a food supplement, with an approximate half-life of 1 to 3 hours, with a total clearance of 6 hours, there are no significant concerns of accumulation (Millar et al., 2018).

The ADME data provides context for interpreting the toxicological data. It is noted that the bioavailability of CBD is typically low but can be affected by food matrices. The food context for CBD could therefore impact on CBD bioavailability. It was noted that the potential for CBD to accumulate in the body has not been examined based on the data supplied. This has been taken into account in considering the assessment factors to account for uncertainty in setting the provisional ADI.

2.9. Nutritional Information

The FSA and FSS sought clarification of the potential for the presence of antinutritional factors from the preparation. It was noted that hemp can contain a range of substances that could impact the digestion and absorption of nutrients from the diet. These include phytic acid (which can negatively affect the bioavailability of dietary and endogenous minerals and proteins), tannins (which can interrupt the absorption of iron), trypsin

inhibitors (which can affect protein digestion), and saponins (which at larger quantities cause gastric irritation and increase the permeability of the intestine).

The product is highly purified as indicated in the information on the composition. There are no substances present that would be expected to impact the digestion or absorption of nutrients from the diet.

The data on nutritional composition confirm that CBD has no caloric or nutritional value. The application is not intending that CBD replace another food in the diet. Consumption of the novel food at the proposed use levels is not expected to be nutritionally disadvantageous for consumers.

2.10. Toxicological Information

Toxicological studies on CBD were performed by the applicant to support the safety assessment of the novel food. The respective study reports are unpublished and claimed as confidential and proprietary data. They were considered essential in the assessment of the safety of the novel food and were reviewed by the ACNFP. How data on systemic toxicity was managed and interpreted in the context of the provisional ADI is explained in the sub-chronic toxicology section below (section 2.10.2).

2.10.1. Genotoxicity

In vitro genotoxicity testing of CBD was conducted under Good Laboratory Practice (GLP) conditions and utilised the following OECD guidelines: *in vitro* bacterial reverse mutation test (OECD TG 471) and *in vitro* mammalian cell micronucleus test (OECD TG 487). This approach is recommended by the UK Committee on Mutagenicity and is also the basis of guidance on the preparation and submission of an application for authorisation of a novel food in the context of assimilated Regulation (EU) 2015/2283.

The *in vitro* bacterial reverse mutation test demonstrated that this CBD ingredient was non-mutagenic, in the absence or presence of metabolic activation. In addition, the *in vitro* mammalian cell micronucleus test demonstrated that CBD was non-clastogenic and non-aneugenic in the absence and presence of metabolic activation.

The results from these *in vitro* studies support the conclusion that the novel food (>98% pure CBD) is not genotoxic. This is consistent with the view of the Committee on Mutagenicity in reviewing CBD generically as a substance from evidence available in the public domain (Committee on Mutagenicity; MUT/MIN/2020/1, 2020).

2.10.2. Sub-chronic toxicology study

A Joint Subgroup of the ACNFP and COT was formed to address a series of questions in relation to the safety of CBD, cannabinoids and hemp-derived ingredients.

The applicant provided a Repeated Dose 13-week Oral Toxicity Study in Rodents [(Labcorp, study number 8462626)], which was conducted under GLP conditions and to OECD Test Guideline 408. In this 90-day study, male and female rats were dosed once a day with 0 (corn oil), 15, 30, or 60 mg/kg bw/day CBD by oral gavage at a dose volume of 5 mL/kg bw. The control group (0 mg/kg bw/day) and high-dose group (60 mg/kg bw/day) both contained 15 male and 15 female rats, and dose groups 15 and 30 mg/kg bw/day both contained 10 male and 10 female rats. Of the control group and high-dose group, 5 males and 5 females were allocated to the recovery period and retained not dosed for 4-weeks.

The applicant concluded a NOAEL of 60 mg/kg bw/day; the Subgroup reviewed the data and concluded a NOAEL from the study of 30 mg/kg bw/day, based on liver enlargement and histopathological changes in the adrenal. The Subgroup considered the critical effect on the liver to be the NOAEL and thus a point of departure (POD) of 30 mg/kg was confirmed by the Subgroup.

The Subgroup reviewed the data and concluded the effects seen at 30 mg/kg bw/day were minimal but not adverse; however the effects seen at 60 mg/kg bw/day are potentially adverse. As such the Subgroup considered that the NOAEL for the study be 30 mg/kg bw/day. A review of the study by the Subgroup supported the conclusion that it was of sufficient quality to support the safety of the novel food.

In addition to the data submitted by the applicant there is a body of evidence on the effect of 98% or greater CBD. In order to take account of all pertinent data and to put the individual assessment in the context of the totality of relevant evidence for the active substance, the data from this application was compared to the wider body of evidence.

A weight of evidence approach allowed the Subgroup to identify a provisional ADI for CBD ingredients of >98% purity of 0.15 mg/kg bw/day or 10 mg per day for a 70 kg healthy adult (Joint position paper from the ACNFP and COT; FSA consumer advice published in October 2023). This value was identified to be protective of the most sensitive known effects in the liver and thyroid parameters and included consideration of data gaps and uncertainties.

The dataset includes several studies where highly purified CBD has been tested. Given the low level of contaminants, it is reasonable to consider that these represent the effect of CBD as a substance and are therefore relevant to other novel foods with similar compositions.

It was considered whether the wider data and therefore the provisional ADI for CBD of 98% or greater purity was relevant to the review of this novel food. It was considered appropriate, on the basis that the test substance used in the study to support the novel food was 98% pure and the compositional data was consistent with a highly purified CBD. The contaminants present were not suggestive of a significant impact on the toxicology. The point of departure in the form of a NOAEL from the study submitted to support safety of this novel food once corrected for CBD content, is consistent with the range of the points of departure used to develop the provisional ADI (ACNFP and COT, 2023). The NOAEL was also based on the same effect – impacts on the liver. The uncertainty factors identified in the provisional ADI would also apply to the applicant's submitted study (Labcorp, study number 8462626 unpublished) for the same reasons as identified in the provisional ADI statement. It was, therefore, considered scientifically appropriate to apply the provisional ADI of 0.15 mg/kg bw/day or 10 mg/day as identified in the joint statement of the ACNFP and COT on ≥98% pure forms of CBD to the novel food in this application.

2.11. Allergenicity

This CBD isolate comprises >98% CBD and the production process for CBD does not introduce any risk of allergenic potential. As a chemical entity the potential for IgE mediated food allergy is unlikely.

Given that CBD as a substance is not considered allergenic, the allergenicity assessment considered whether the other 2% of the novel foods' composition was likely to be allergenic or elicit food allergic reactions. It was noted that none of the raw materials or processing aids used in the production process are derived from or contain any of the allergenic food ingredients specified under assimilated Regulation (EU) No 1169/2011 on the provision of food information to consumers. This suggests that the potential to elicit reactions in those sensitive to those foods is unlikely.

The novel food is unlikely to trigger allergic reactions in the target population under the proposed conditions of use.

3. Discussion

The novel food is a CBD isolate ingredient from industrial hemp containing >98% CBD, produced using a multi-step manufacturing process.

This CBD isolate is intended to be used as a food ingredient in food supplements for adults, excluding pregnant and lactating women, and other specifically identified vulnerable groups at a defined intake for each product type of up to 10 mg CBD per day; it is not intended to replace any food.

In October 2023, the Joint ACNFP and COT Subgroup identified a provisional acceptable daily intake (ADI) of 10 mg per day (0.15 mg/kg bw/day) for CBD products containing 98% CBD or above, such as the novel food discussed in this assessment. A weight of evidence approach was used to arrive at a provisional ADI of 10 mg/day (0.15 mg/kg bw/day). The most sensitive human health effects, which this provisional ADI protects against, are seen consistently in the liver and thyroid in a number of studies using $\geq 98\%$ pure CBD. This value also takes account of the lack of human-based long-term evidence or evidence regarding potentially vulnerable groups.

Based upon the dossier of evidence provided by the applicant, the safety of the novel food was reviewed and evidence to reach a conclusion on safety provided. The evidence presented by the applicant was then compared to the wider data set on CBD, and the evidence presented is consistent with evidence presented to support the development of a provisional ADI of 10 mg/day for CBD of 98% purity or above. As such it is appropriate to apply the provisional ADI to this novel food.

This is subject to the existing advice to consumers that pregnant and breastfeeding women, and people taking any prescription medication, should avoid the consumption of CBD. Consumers on regular medications should seek advice from a medical professional before using any type of CBD food product. In addition, children and prospective parents trying for a baby are advised against consumption of CBD, as are those who are immunosuppressed, due to remaining data gaps and residual uncertainties concerning the safety of CBD for these groups of consumers. These contraindications would also apply to this novel food.

The maximum safe exposure for healthy adults of 70 kg as identified in the provisional ADI is 10 mg per day from all food sources. If the inclusion level of this CBD isolate leads to an intake per individual serving of each product type of 10 mg/day, multiple intakes of food products containing CBD on the same day should be avoided to support minimising exposure to below the provisional ADI.

4. Conclusions

The FSA and FSS have undertaken the assessment of CBD isolate and both concluded that the novel food is safe under the proposed conditions of use and does not pose a safety risk to human health. The anticipated intake levels and the proposed use was not considered to be nutritionally disadvantageous.

These conclusions were supported by the information in the novel food dossier submitted by the applicant plus the supplementary information and could not have been reached without the following data claimed as proprietary by the applicant:

- annexes to the dossier which relate to the identity of the novel food, the production process, stability, methods of analysis, particle size analysis and toxicology;
- *in vitro* bacterial reverse mutation test [(Labcorp study number 8462622)], *in vitro* mammalian cell micronucleus test [(Labcorp study number 8242623)] and 13-weeks repeat dose feeding study [(Labcorp study number 8462626)].

Abbreviations

Abbreviation	Definition
ACNFP	Advisory Committee on Novel Foods and Processes
ADI	Acceptable daily intake
ADME	Absorption, Distribution, Metabolism and Excretion
AOAC	Association of Official Analytical Chemists
ARfD	Acute reference dose
a_w	Water activity
bw	Body weight
CAS	Chemical Abstracts Service
CBD	Cannabidiol
Cmax	Peak serum concentration
COT	Committee on Toxicity
CFU	Colony forming unit
DSC	Differential scanning calorimetry
EC	European Commission
EDA	Energy dispersive X-ray
EFSA	European Food Safety Authority
EMA	Environmental Medicines Agency
EU	European Union
FDA	Food and Drug Administration (USA)

Abbreviation	Definition
FSA	Food Standards Agency
FSS	Food Standards Scotland
FTIR	Fourier-transform infrared spectroscopy
GC	Gas chromatography
GLP	Good Laboratory Practice
HACCP	Hazards Analysis and Critical Control Points
HPLC	High performance liquid chromatography
HS	Headspace
ICP-MS	Inductively coupled plasma mass spectrometry
LC-MS	Liquid chromatography-mass spectrometry
LOAEL	Lowest observed adverse effect level
LOD	Limit of detection
LOQ	Limit of quantification
MS	Mass spectrometry
ND	Not determined
NOAEL	No observed adverse effect level
NM	Not measured
OECD	Organisation for Economic Co-operation and Development
Ph.Eur	European Pharmacopeia
TGA	Thermogravimetric analysis
Tmax	Time to maximum concentration
USP	United States Pharmacopeia
UV	Ultra-violet
XRD	X-ray diffraction

Acknowledgements

With thanks to the members of the ACNFP during the course of the assessment who were; Dr Camilla Alexander White, Dr Anton Alldrick, Dr Kimon Andreas Karatzas, Ms Alison Austin, Dr Mark Berry, Professor George Bassel, Dr Christine Bosch, Professor Dimitris Charalampopoulos, Dr Cathrina Edwards, Professor Susan Fairweather-Tait, Professor Paul Fraser, Dr Hamid Ghodusi, Dr Andy Greenfield, Professor Wendy Harwood, Professor Huw D. Jones, Dr Ray Kemp, Dr Elizabeth Lund, Professor Harry J. McArdle, Rebecca McKenzie, Professor Clare Mills, Dr Antonio Peña-Fernández, Dr Lesley Stanley, Professor Hans Verhagen, Dr Maureen Wakefield, and Professor Bruce Whitelaw.

To note, interests were received from members of the ACNFP: Dr Alldrick declared a potential interest relating to his previous employment; this was considered a potential conflict and as a result he was not present for discussions of CBD by the Committee. Emeritus Prof Harry McArdle declared an interest from his work with EFSA's novel food Committee in

considering data requirements for CBD. While not seen as a conflict, to avoid Prof McArdle being subject to information that would influence his EFSA work, it was agreed that he would not be present in discussions for CBD by the ACNFP but could supply comments for consideration by the Committee upon review of the minutes.

Published: February 28, 2025 GMT.



This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY-4.0). View this license's legal deed at <http://creativecommons.org/licenses/by/4.0> and legal code at <http://creativecommons.org/licenses/by/4.0/legalcode> for more information.

References

- Advisory Committee on Novel Foods and Processes (ACNFP) & Committee on Toxicity (COT). (2023). *Joint position paper from the Advisory Committee on Novel Foods and Processes (ACNFP) & Committee on Toxicity (COT) on establishing a provisional acceptable daily intake (ADI) for pure form (≥98%) cannabidiol (CBD) in foods, based on new evidence.* <https://doi.org/10.46756/sci.fsa.zcg392>
- Committee On Mutagenicity Of Chemicals In Food, Consumer Products And The Environment, (MUT/MIN/2020/1). (2020). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/967784/Final_COM_mins_February_2020.pdf#:~:text=The%20Committee%20on%20the%20Toxicity%20of%20Chemicals%20in,requested%20a%20COM%20view%20of%20the%20genotoxicity%20data
- Committee On Toxicity Of Chemicals In Food, Consumer Products And The Environment. (2020). <https://cot.food.gov.uk/sites/default/files/tox202002cbd.pdf>
- Devinsky, O., Patel, A. D., Thiele, E. A., Wong, M. H., Appleton, R., Harden, C. L., Greenwood, S., Morrison, G., & Sommerville, K. (2018). Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome [GWPCARE1 Part A Study Group]. *Neurology*, *90*, e1204–e1211. <https://doi.org/10.1212/WNL.0000000000005254>
- EFSA CONTAM Panel. (2015). *Scientific opinion on the risks for human health related to the presence of Tetrahydrocannabinol (THC) in milk and other food from animal origin.* <https://doi.org/10.2903/j.efsa.2015.4141>
- EFSA NDA Panel (EFSA Panel on Nutrition and Novel Foods). (2016). Guidance on the Preparation and Presentation of an Application for Authorisation of a Novel Food in the Context of Regulation (EU) 2015/2283. *EFSA Journal*, *14*(11), 4594. <https://doi.org/10.2903/j.efsa.2016.4594>
- Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. *Clinical Pharmacokinetics*, *42*(4), 327–360. <https://doi.org/10.2165/00003088-200342040-00003>
- Hawksworth, G., & McArdle, K. (2004). Metabolism and pharmacokinetics of cannabinoids. In G. Guy, B. Whittle, & P. Robson (Eds.), *The Medicinal Uses of Cannabis and Cannabinoids* (pp. 205–228). London Pharmaceutical Press.
- Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019). Cannabidiol Adverse Effects and Toxicity. *Curr Neuropharmacol*, *17*(10), 974–989. <https://doi.org/10.2174/1570159X17666190603171901>
- Izegelov, D., Davidson, E., Barasch, D., Regev, A., Domb, A. J., & Hoffman, A. (2020). Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers. *Eur J Pharm Biopharm*, *154*, 108–115. <https://doi.org/10.1016/j.ejpb.2020.06.021>

- Jiang, R., Yamaori, S., Takeda, S., Yamamoto, I., & Watanabe, K. (2011). Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. *Life Sciences*, 89(5–6), 165–170. <https://doi.org/10.1016/j.lfs.2011.05.018>
- Johnson, D. A., Funnell, M., Heaney, L., Cable, T., Bailey, S., Clifford, T., & James, L. J. (2022). *A Pharmacokinetic comparison of 70 mg cannabidiol ingested orally via gelatin capsules versus sublingual drops*. Loughborough University.
- Klotz, K. A., Grob, D., Hirsch, M., Metternich, B., Schulze-Bonhage, A., & Jacobs, J. (2019). Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy. *Front Neurol*, 10, 1313. <https://doi.org/10.3389/fneur.2019.01313>
- Kraemer, M., Broecker, S., Madea, B., & Hess, C. (2019). Decarbonylation: A metabolic pathway of cannabidiol in humans. *Drug Test Anal*, 11(7), 957–967. <https://doi.org/10.1002/dta.2572>
- Labcorp. (2021). *Labcorp Early Development Laboratories Limited, Huntingdon, Cambridgeshire, UK. Study Title: Cannabidiol: Toxicity study by oral gavage administration to Han Wistar Rats for 13 weeks followed by a 4-week recovery period. Final report. Confidential. (Study No: 8462626)*.
- Labcorp. (2022a). *Labcorp Early Development Laboratories Limited, Huntingdon, Cambridgeshire, UK. Study Title: Cannabidiol: bacterial reverse mutation test. Final report. Confidential. (Study No: 8462622)*.
- Labcorp. (2022b). *Labcorp Early Development Laboratories Limited, Huntingdon, Cambridgeshire, UK. Study Title: Cannabidiol: In vitro micronucleus test in human lymphocytes. Final report. Confidential. (Study No: 8462623)*.
- Labcorp. (2022c). *Labcorp Early Development Laboratories Limited, Huntingdon, Cambridgeshire, UK. Study Title: Cannabidiol: Toxicity study by oral gavage administration to Han Wistar Rats for 13 weeks followed by a 4-week recovery period. Final report. Confidential. (Study No: 8462626)*.
- Martin-Santos, R., Crippa, J. A., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., Allen, P., Seal, M., Langohr, K., Farré, M., Zuardi, A. W., & McGuire, P. K. (2012). Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. *Current Pharmaceutical Design*, 18(32), 4966–4979. <https://doi.org/10.2174/138161212802884780>
- Mechoulam, R., Parker, L. A., & Gallily, R. (2002). Cannabidiol: an overview of some pharmacological aspects. *Journal of Clinical Pharmacology*, 42, 115–195. <https://doi.org/10.1002/j.1552-4604.2002.tb05998.x>
- Millar, S. A., Stone, N. L., Yates, A. S., & O'Sullivan, S. E. (2018). A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. *Frontiers in Pharmacology*, 9, 1365. <https://doi.org/10.3389/fphar.2018.01365>

Sellers, E. M., Schoedel, K., Bartlett, C., Romach, M., Russo, E. B., Stott, C. G., Wright, S., White, L., Duncombe, P., & Chen, C. F. (2013). A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray. *Clin Pharmacol Drug Dev*, 2(3), 285–294. <https://doi.org/10.1002/cpdd.36>

Stero Biotechs Ltd. (2020, June 30). *Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients*. ClinicalTrials.Gov Identifier: NCT04056442. <https://classic.clinicaltrials.gov/ct2/show/NCT04056442?term=Phase+2a+Study+to+Evaluate+the+Safety%2C+Tolerability+and+Efficacy+of+Cannabidiol+as+a+Steroid-sparing+Therapy+in+Steroid-dependent+Crohn%27s+Disease+Patients&draw=2&rank=1>

Stott, C. G., White, L., Wright, S., Wilbraham, D., & Guy, G. W. (2013). A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. *Eur J Clin Pharmacol*, 69(5), 1135–1147. <https://doi.org/10.1007/s00228-012-1441-0>

Taylor, L., Gidal, B., Blakey, G., Tayo, B., & Morrison, G. (2018). A Phase I, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. *CNS Drugs*, 32(11), 1053–1067. <https://doi.org/10.1007/s40263-018-0578-5>

Wheless, J. W., Dlugos, D., Miller, I., Oh, D. A., Parikh, N., Phillips, S., Renfroe, J. B., Roberts, C. M., Saeed, I., Sparagana, S. P., Yu, J., Cilio, M. R., & INS011-14-029 Study Investigators. (2019). Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy. *CNS Drugs*, 33(6), 593–604. <https://doi.org/10.1007/s40263-019-00624-4>

WHO (World Health Organization). (2018). Cannabidiol (CBD) critical review report. In *40th Meeting - Expert Committee on Drug Dependence*. <https://www.who.int/medicines/access/controlled-substances/CannabidiolCriticalReview.pdf>

Zendulka, O., Dovrtělová, G., Nosková, K., Turjap, M., Šulcová, A., Hanuš, L., & Juřica, J. (2016). Cannabinoids and Cytochrome P450 Interactions. *Current Drug Metabolism*, 17(3), 206–226. <https://doi.org/10.2174/1389200217666151210142051>